Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy

Hongzhi Lin,Yuting Qiao,Hongyu Yang,Qin Nan,Wei Qu,Feng Feng,Wenyuan Liu,Yao Chen,Haopeng Sun

DOI: https://doi.org/10.4155/fmc-2019-0285

2020-01-01

Future Medicinal Chemistry

Abstract:The basic leucine zipper transcription factor Nrf2 is the primary regulator of cellular oxidative stress. Activation of Nrf2 is regarded as a potential preventive and therapeutic strategy. However, aberrant hyperactivation of Nrf2 is found in a variety of cancers and promotes cancer progression and metastasis. Moreover, constitutive activation of Nrf2 confers cancer cells resistance to chemo- and radio-therapy. Thus, inhibiting Nrf2 could be a new therapeutic strategy for cancer. With the aim of accelerating the discovery and development of novel Nrf2 inhibitors, we summarize the biological and pathological functions of Nrf2 in cancer. Furthermore, the recent studies of small molecular Nrf2 inhibitors and potential Nrf2 inhibitory mechanisms are also summarized in this review. [GRAPHICS] .